APLM
Apollomics Inc. Class A
stockNASDAQ
formerly known as cbt pharmaceuticals. at apollomics, we are a purpose driven company imagining a world without cancer. we let science drive our decision making to advance our programs. we believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve. apollomics is committed to the discovery and development of oncology combination therapies. we believe that combination regimens can achieve clinically meaningful, durable responses that will allow us to enhance outcomes for patients. we have in-licensed our assets from multiple partners and built strong collaborations to advance our pre-clinical and clinical development programs. when developing an asset, we begin with rigorous ind-enabling studies to establish sound mechanistic and scientific rationale and guide our development path. this path may be as a monotherapy, a combination therapy, or both. while our ultimate goal is to study each of our assets in combination with other agents, we h
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 19.97 | 2026-10-28 | +4.21% | 2.341 |
| 1M | 23.27 | 2026-10-01 | -10.56% | -1.060 |
| 3M | 17.58 | 2026-08-04 | +18.41% | 0.039 |
| 6M | 16.47 | 2026-05-04 | +26.39% | 0.018 |
| 1Y | 14.17 | 2025-11-03 | +46.86% | 0.511 |
| 2Y | 11.40 | 2024-11-04 | +82.54% | — |
| 5Y | 2,940.00 | 2023-03-30 | -99.29% | 0.451 |
Apollomics Inc. Class A (NASDAQ:APLM) stock price today is $20.81, and today's volume is 1,810. APLM is down 0.144% today. The 30 day average volume is 13,597. APLM market cap is $60.66M with 2.91M shares outstanding.